Changzheng Wang

机构：Xerox (France), Fudan University Shanghai Cancer Center, Chongqing Medical University, Kentucky State University · ORCID：0000-0002-8991-1315

发表论文 146 篇 · 总被引 5244 次 · h-index 30

代表论文

• Preliminary study to identify severe from moderate cases of COVID-19 using combined hematology parameters (2020 · Annals of Translational Medicine · 被引 230)
• Red cell distribution width (RDW): a prognostic indicator of severe COVID-19 (2020 · Annals of Translational Medicine · 被引 87)
• Severe eosinophilic asthma in Chinese C‐BIOPRED asthma cohort (2022 · Clinical and Translational Medicine · 被引 29)
• Patterns in genomic mutations among patients with early-onset colorectal cancer: an international, multicohort, observational study (2025 · The Lancet Oncology · 被引 26)
• Asthma Management Using the Mobile Asthma Evaluation and Management System in China (2022 · Allergy Asthma and Immunology Research · 被引 12)
• Eligibility of C-BIOPRED severe asthma cohort for type-2 biologic therapies (2023 · Chinese Medical Journal · 被引 8)